Your browser doesn't support javascript.
loading
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).
Shi, Yuankai; Chen, Jianhua; Zhang, Helong; Zhang, Zhihong; Zhang, Yiping; Wang, Zhehai; Zhang, Shucai; Zhao, Jian; Liu, Chunling; Wang, Xiuwen; Zhao, Yanqiu; Hu, Changlu; Yang, Lei; Hao, Xuezhi; Wang, Lin; Liu, Yunpeng; Yu, Yan; Zhao, Jun; Wang, Mengzhao; Zhang, Liangming; Sun, Sanyuan; Hu, Yanping; Gu, Kangsheng; Hang, Xiaosheng; Shan, Jinlu; Zhang, Yu; Tan, Bangxian; Yang, Weihua; Yang, Runxiang; Si, Meimei; Geng, Huaize; Li, Hui; Kang, Xiaoyan.
Affiliation
  • Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. syuankai@cicam
  • Chen J; Thoracic Medicine Department I, Hunan Tumor Hospital, Changsha, China.
  • Zhang H; Oncology Department, the Second Affiliated Hospital of Air Force Medical University, Xi'an, China.
  • Zhang Z; Department of Respiratory Oncology, Anhui Provincial Cancer Hospital, Hefei, China.
  • Zhang Y; Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Wang Z; Respiratory Medical Oncology Ward II, Shandong Provincial Institute of Cancer Prevention and Treatment, Jinan, China.
  • Zhang S; Oncology Department II, Beijing Chest Hospital, Capital Medical University, Beijing, China.
  • Zhao J; Thoracic Surgery I, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
  • Liu C; Pulmonary Medicine Ward II, The Affiliated Tumour Hospital of Xingjiang Medical University, Urumqi, China.
  • Wang X; Chemotherapy Department, Qilu Hospital of Shandong University, Jinan, China.
  • Zhao Y; Respiratory Medicine Ward I, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Hu C; Ward IV of Department of Oncology, Anhui Provincial Cancer Hospital, Hefei, China.
  • Yang L; Department of Respiratory Oncology, Gansu Province Cancer Hospital, Lanzhou, China.
  • Hao X; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
  • Wang L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
  • Liu Y; Department of Medical Oncology Ward II, The First Hospital of China Medical University, Shenyang, China.
  • Yu Y; Respiratory Medicine Ward III, Harbin Medical University Cancer Hospital, Harbin, China.
  • Zhao J; Department of Thoracic Oncology I, Peking University Cancer Hospital, Beijing, China.
  • Wang M; Department of Pulmonary and Critical care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Zhang L; Oncology Department, Yantai Yuhuangding Hospital, Yantai, China.
  • Sun S; Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou, China.
  • Hu Y; Thoracic Oncology (2), Hubei Cancer Hospital, Wuhan, China.
  • Gu K; Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Hang X; Medical Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China.
  • Shan J; Oncology Department, Army Medical Center of PLA, Chongqing, China.
  • Zhang Y; Respiratory Department, Nanjing Chest Hospital, Medical School of Southeast University, Nanjing, China.
  • Tan B; Department of Oncology, Affiliated Hospital of North Sichuan Medical college, Nanchong, China.
  • Yang W; Department of Respiratory, Shanxi Provincial Cancer Hospital, Taiyuan, China.
  • Yang R; The Second Department of Medical Oncology, Yunnan Cancer Hospital, Kunming, China.
  • Si M; Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China.
  • Geng H; Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China.
  • Li H; Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China.
  • Kang X; Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China.
BMC Med ; 21(1): 72, 2023 02 24.
Article in En | MEDLINE | ID: mdl-36829154
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Clinical_trials Limits: Adolescent / Adult / Humans Language: En Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Clinical_trials Limits: Adolescent / Adult / Humans Language: En Year: 2023 Type: Article